Uveitis - Pipeline Review, H1 2018

Date: March 20, 2018
Pages: 195
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U8BD67BCFFDEN
Leaflet:

Download PDF Leaflet

Uveitis - Pipeline Review, H1 2018
Uveitis - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2018, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 6, 4, 1, 27 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Uveitis - Overview
Uveitis - Therapeutics Development
Uveitis - Therapeutics Assessment
Uveitis - Companies Involved in Therapeutics Development
Uveitis - Drug Profiles
Uveitis - Dormant Projects
Uveitis - Discontinued Products
Uveitis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Uveitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Uveitis - Pipeline by AbbVie Inc, H1 2018
Uveitis - Pipeline by Aciont Inc, H1 2018
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H1 2018
Uveitis - Pipeline by Apitope International NV, H1 2018
Uveitis - Pipeline by Bionomics Ltd, H1 2018
Uveitis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Uveitis - Pipeline by Clearside BioMedical Inc, H1 2018
Uveitis - Pipeline by Coherus BioSciences Inc, H1 2018
Uveitis - Pipeline by Elasmogen Ltd, H1 2018
Uveitis - Pipeline by Endocyte Inc, H1 2018
Uveitis - Pipeline by Enzo Biochem Inc, H1 2018
Uveitis - Pipeline by EyeGate Pharmaceuticals Inc, H1 2018
Uveitis - Pipeline by Eyevensys SAS, H1 2018
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Uveitis - Pipeline by Galapagos NV, H1 2018
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Uveitis - Pipeline by Icon Bioscience Inc, H1 2018
Uveitis - Pipeline by Idera Pharmaceuticals Inc, H1 2018
Uveitis - Pipeline by Johnson & Johnson, H1 2018
Uveitis - Pipeline by Kv1.3 Therapeutics, H1 2018
Uveitis - Pipeline by Midatech Pharma Plc, H1 2018
Uveitis - Pipeline by Mitotech SA, H1 2018
Uveitis - Pipeline by Nemus Bioscience Inc, H1 2018
Uveitis - Pipeline by Novartis AG, H1 2018
Uveitis - Pipeline by OncoNOx ApS, H1 2018
Uveitis - Pipeline by Ophthotech Corp, H1 2018
Uveitis - Pipeline by Orchid Pharma Ltd, H1 2018
Uveitis - Pipeline by Oxular Ltd, H1 2018
Uveitis - Pipeline by Palatin Technologies Inc, H1 2018
Uveitis - Pipeline by Panoptes Pharma GesmbH, H1 2018
Uveitis - Pipeline by pSivida Corp, H1 2018
Uveitis - Pipeline by Re-Pharm Ltd, H1 2018
Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018
Uveitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
Uveitis - Pipeline by SynDevRx Inc, H1 2018
Uveitis - Pipeline by TxCell SA, H1 2018
Uveitis - Dormant Projects, H1 2018
Uveitis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Uveitis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Uveitis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Uveitis - Discontinued Products, H1 2018

LIST OF FIGURES

Number of Products under Development for Uveitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc
Aciont Inc
Aldeyra Therapeutics Inc
Apitope International NV
Bionomics Ltd
Bristol-Myers Squibb Co
Clearside BioMedical Inc
Coherus BioSciences Inc
Elasmogen Ltd
Endocyte Inc
Enzo Biochem Inc
EyeGate Pharmaceuticals Inc
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Galapagos NV
HanAll Biopharma Co Ltd
Icon Bioscience Inc
Idera Pharmaceuticals Inc
Johnson & Johnson
Kv1.3 Therapeutics
Midatech Pharma Plc
Mitotech SA
Nemus Bioscience Inc
Novartis AG
OncoNOx ApS
Ophthotech Corp
Orchid Pharma Ltd
Oxular Ltd
Palatin Technologies Inc
Panoptes Pharma GesmbH
pSivida Corp
Re-Pharm Ltd
Santen Pharmaceutical Co Ltd
Sun Pharma Advanced Research Company Ltd
SynDevRx Inc
TxCell SA
Skip to top


Anterior Uveitis - Pipeline Review, H1 2016 US$ 2,000.00 Mar, 2016 · 59 pages
Uveitis - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 208 pages
Anterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 55 pages
Posterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 65 pages
Posterior Uveitis - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 64 pages

Ask Your Question

Uveitis - Pipeline Review, H1 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: